Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rheumatic Heart Disease | 6 | 2015 | 13 | 2.180 |
Why?
|
| Tertiary Care Centers | 2 | 2018 | 80 | 1.180 |
Why?
|
| Rheumatic Fever | 3 | 2015 | 4 | 1.030 |
Why?
|
| Myocarditis | 2 | 2015 | 2 | 0.900 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2015 | 39 | 0.890 |
Why?
|
| Dextrocardia | 2 | 2018 | 3 | 0.760 |
Why?
|
| Cardiac Catheterization | 3 | 2018 | 6 | 0.650 |
Why?
|
| Child | 14 | 2024 | 2242 | 0.630 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2018 | 3 | 0.620 |
Why?
|
| Takayasu Arteritis | 1 | 2018 | 6 | 0.610 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 7 | 0.610 |
Why?
|
| Child, Preschool | 12 | 2024 | 1748 | 0.600 |
Why?
|
| Hospitals, Public | 1 | 2018 | 45 | 0.600 |
Why?
|
| Echocardiography | 4 | 2020 | 100 | 0.590 |
Why?
|
| Public Sector | 1 | 2018 | 82 | 0.570 |
Why?
|
| Humans | 32 | 2024 | 14537 | 0.560 |
Why?
|
| Angiography | 2 | 2018 | 6 | 0.520 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2024 | 47 | 0.490 |
Why?
|
| Retrospective Studies | 5 | 2018 | 799 | 0.480 |
Why?
|
| Male | 21 | 2024 | 6754 | 0.470 |
Why?
|
| Mitral Valve | 1 | 2014 | 12 | 0.470 |
Why?
|
| Treatment Outcome | 7 | 2024 | 889 | 0.460 |
Why?
|
| Infant | 11 | 2024 | 2244 | 0.450 |
Why?
|
| Adolescent | 8 | 2024 | 2985 | 0.400 |
Why?
|
| Female | 18 | 2024 | 9103 | 0.400 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 21 | 0.390 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2010 | 1 | 0.360 |
Why?
|
| Early Diagnosis | 1 | 2010 | 82 | 0.350 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 472 | 0.320 |
Why?
|
| Aorta | 2 | 2010 | 43 | 0.320 |
Why?
|
| Incidence | 3 | 2018 | 685 | 0.310 |
Why?
|
| Heart Failure | 3 | 2024 | 38 | 0.300 |
Why?
|
| Electrocardiography | 6 | 2020 | 35 | 0.290 |
Why?
|
| Valsartan | 1 | 2024 | 1 | 0.240 |
Why?
|
| Aminobutyrates | 1 | 2024 | 1 | 0.240 |
Why?
|
| Tetrazoles | 1 | 2024 | 1 | 0.240 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2024 | 1 | 0.240 |
Why?
|
| Biphenyl Compounds | 1 | 2024 | 4 | 0.240 |
Why?
|
| Enalapril | 1 | 2024 | 7 | 0.240 |
Why?
|
| Time Factors | 3 | 2018 | 507 | 0.240 |
Why?
|
| Drug Combinations | 1 | 2024 | 42 | 0.240 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2015 | 4 | 0.230 |
Why?
|
| Steroids | 2 | 2015 | 14 | 0.230 |
Why?
|
| Aspirin | 2 | 2015 | 15 | 0.220 |
Why?
|
| South Africa | 5 | 2018 | 7596 | 0.220 |
Why?
|
| HIV-1 | 1 | 2012 | 1260 | 0.220 |
Why?
|
| Aortic Coarctation | 1 | 2003 | 1 | 0.210 |
Why?
|
| Catheterization | 1 | 2003 | 6 | 0.210 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 187 | 0.210 |
Why?
|
| Hemorheology | 1 | 2002 | 1 | 0.210 |
Why?
|
| Discrete Subaortic Stenosis | 1 | 2002 | 1 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 244 | 0.210 |
Why?
|
| Fontan Procedure | 1 | 2002 | 1 | 0.200 |
Why?
|
| Heart Ventricles | 1 | 2002 | 60 | 0.190 |
Why?
|
| Diagnosis, Differential | 4 | 2010 | 63 | 0.180 |
Why?
|
| Acute Chest Syndrome | 1 | 2020 | 1 | 0.180 |
Why?
|
| Arginine | 1 | 2020 | 5 | 0.180 |
Why?
|
| Length of Stay | 1 | 2020 | 43 | 0.180 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 8 | 0.170 |
Why?
|
| Myocardial Ischemia | 1 | 2020 | 12 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 13 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1999 | 2 | 0.160 |
Why?
|
| Myxoma | 1 | 1999 | 3 | 0.160 |
Why?
|
| Heart Atria | 1 | 1999 | 7 | 0.160 |
Why?
|
| Heart Neoplasms | 1 | 1999 | 5 | 0.160 |
Why?
|
| Tetralogy of Fallot | 1 | 1998 | 1 | 0.160 |
Why?
|
| Endocarditis | 1 | 1998 | 4 | 0.160 |
Why?
|
| Prenatal Diagnosis | 1 | 2018 | 22 | 0.160 |
Why?
|
| Septal Occluder Device | 1 | 2018 | 2 | 0.150 |
Why?
|
| Infant, Newborn | 4 | 2018 | 1479 | 0.150 |
Why?
|
| Prosthesis Design | 1 | 2018 | 11 | 0.150 |
Why?
|
| Africa, Southern | 1 | 2018 | 91 | 0.150 |
Why?
|
| Survival Rate | 1 | 2018 | 96 | 0.150 |
Why?
|
| Prognosis | 1 | 2018 | 199 | 0.150 |
Why?
|
| Tachycardia, Ectopic Junctional | 1 | 1997 | 1 | 0.150 |
Why?
|
| Pericarditis | 2 | 2004 | 4 | 0.140 |
Why?
|
| Cause of Death | 1 | 2018 | 221 | 0.140 |
Why?
|
| Endocarditis, Bacterial | 1 | 1995 | 7 | 0.130 |
Why?
|
| Thoracic Wall | 1 | 2015 | 2 | 0.130 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2015 | 2 | 0.130 |
Why?
|
| Africa | 2 | 2015 | 376 | 0.130 |
Why?
|
| Staphylococcal Infections | 1 | 1995 | 31 | 0.120 |
Why?
|
| Morbidity | 1 | 2015 | 37 | 0.120 |
Why?
|
| Bacteremia | 1 | 1995 | 79 | 0.120 |
Why?
|
| Prevalence | 1 | 2018 | 1192 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2014 | 64 | 0.110 |
Why?
|
| Risk Factors | 1 | 2018 | 1475 | 0.110 |
Why?
|
| Hospitals | 1 | 2014 | 103 | 0.110 |
Why?
|
| HIV Infections | 1 | 2012 | 5097 | 0.110 |
Why?
|
| Double-Blind Method | 3 | 2024 | 272 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2024 | 1160 | 0.110 |
Why?
|
| Pregnancy | 1 | 2018 | 1862 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 411 | 0.100 |
Why?
|
| Heart Defects, Congenital | 2 | 2004 | 12 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 370 | 0.090 |
Why?
|
| Thoracic Surgery | 1 | 2011 | 2 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 6 | 0.090 |
Why?
|
| Collateral Circulation | 1 | 2010 | 1 | 0.090 |
Why?
|
| Pulmonary Circulation | 1 | 2010 | 1 | 0.090 |
Why?
|
| Pulmonary Atresia | 1 | 2010 | 1 | 0.090 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2010 | 2 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 4 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 4 | 0.090 |
Why?
|
| Pediatrics | 1 | 2011 | 17 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2010 | 21 | 0.090 |
Why?
|
| Biopsy | 1 | 2010 | 38 | 0.090 |
Why?
|
| Myocardium | 1 | 2010 | 35 | 0.090 |
Why?
|
| Nigeria | 2 | 2020 | 49 | 0.090 |
Why?
|
| HIV Antibodies | 1 | 2012 | 247 | 0.080 |
Why?
|
| Heart Valve Diseases | 1 | 2006 | 6 | 0.070 |
Why?
|
| Forecasting | 1 | 2006 | 20 | 0.070 |
Why?
|
| Primary Prevention | 1 | 2006 | 27 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2002 | 4 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2004 | 5 | 0.060 |
Why?
|
| Neprilysin | 1 | 2024 | 3 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2024 | 7 | 0.060 |
Why?
|
| Cyanoacrylates | 1 | 2004 | 1 | 0.060 |
Why?
|
| Arteriovenous Fistula | 1 | 2004 | 2 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2004 | 4 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2024 | 29 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2024 | 37 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2024 | 43 | 0.060 |
Why?
|
| Alprostadil | 1 | 2004 | 3 | 0.060 |
Why?
|
| Hyperostosis | 1 | 2004 | 3 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2004 | 30 | 0.060 |
Why?
|
| Stents | 1 | 2003 | 10 | 0.050 |
Why?
|
| Recurrence | 1 | 2003 | 29 | 0.050 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2002 | 1 | 0.050 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2002 | 1 | 0.050 |
Why?
|
| Exercise Tolerance | 1 | 2002 | 4 | 0.050 |
Why?
|
| Patient Selection | 1 | 2002 | 40 | 0.050 |
Why?
|
| Thrombosis | 1 | 2002 | 47 | 0.050 |
Why?
|
| Radiography | 2 | 2015 | 80 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2020 | 127 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 1997 | 279 | 0.040 |
Why?
|
| Pulmonary Veins | 1 | 1999 | 1 | 0.040 |
Why?
|
| Esophageal and Gastric Varices | 1 | 1999 | 2 | 0.040 |
Why?
|
| Atenolol | 1 | 1979 | 2 | 0.040 |
Why?
|
| Propanolamines | 1 | 1979 | 8 | 0.040 |
Why?
|
| Echocardiography, Doppler | 1 | 1998 | 18 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 480 | 0.040 |
Why?
|
| Sotalol | 1 | 1997 | 1 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 1997 | 1 | 0.040 |
Why?
|
| Myocardial Infarction | 3 | 1982 | 24 | 0.040 |
Why?
|
| Digoxin | 1 | 1997 | 6 | 0.040 |
Why?
|
| Amiodarone | 1 | 1997 | 2 | 0.040 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1997 | 2 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1997 | 2 | 0.040 |
Why?
|
| Blood Pressure | 1 | 1979 | 317 | 0.030 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2015 | 2 | 0.030 |
Why?
|
| Poland Syndrome | 1 | 2015 | 2 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 1995 | 43 | 0.030 |
Why?
|
| Cross Infection | 1 | 1995 | 52 | 0.030 |
Why?
|
| Disease Progression | 1 | 1995 | 154 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1422 | 0.030 |
Why?
|
| Hypertension | 1 | 1979 | 419 | 0.030 |
Why?
|
| Exercise Test | 2 | 1982 | 13 | 0.020 |
Why?
|
| Aortography | 1 | 2010 | 3 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2010 | 7 | 0.020 |
Why?
|
| Middle Aged | 5 | 2004 | 3601 | 0.020 |
Why?
|
| Aged | 4 | 2004 | 1740 | 0.020 |
Why?
|
| Chest Pain | 1 | 2004 | 3 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 7 | 0.010 |
Why?
|
| Acute Kidney Injury | 1 | 2004 | 15 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 16 | 0.010 |
Why?
|
| Syphilis, Congenital | 1 | 2004 | 13 | 0.010 |
Why?
|
| Osteomyelitis | 1 | 2004 | 9 | 0.010 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 1999 | 1 | 0.010 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 1979 | 1 | 0.010 |
Why?
|
| Pulse | 1 | 1979 | 3 | 0.010 |
Why?
|
| Placebos | 1 | 1979 | 44 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1979 | 112 | 0.010 |
Why?
|
| Adult | 4 | 1982 | 5913 | 0.010 |
Why?
|